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Cells sense and respond to the extracellular matrix (ECM) by way of integrin receptors, which facilitate cell adhesion and
intracellular signaling. Advances in understanding the mammary epithelial cell hierarchy are converging with new developments
that reveal how integrins regulate the normal mammary gland. But in breast cancer, integrin signaling contributes to the
development and progression of tumors. This paper highlights recent studies which examine the role of integrin signaling in
mammary epithelial cells and their malignant counterparts.
1.Introduction
The extracellular matrix (ECM)—composed of numerous
insoluble proteins secreted locally by epithelial and stromal
cells—provides physical support to organize neighboring
cells within a tissue and serves as a reservoir of growth
factors. In the mammary gland, ECM interactions can
control epithelial cell proliferation, survival, migration, and
diﬀerentiation to regulate processes such as branching mor-
phogenesis, polarization of mammary ducts and the alveolar
outgrowth, and involution that occurs with pregnancy [1].
However, the matrix, which constitutes one component of
the diverse tumor microenvironment, changes dramatically
during the process of breast tumorigenesis and can strongly
aﬀect disease progression [2]. Therefore, the ECM can exert
a strong inﬂuence on both normal and tumor cells.
In either case, cells sense and respond to the ECM by
way of transmembrane integrin receptors, which recognize
and bind to various ECM proteins and thereby facilitate
cell adhesion and intracellular signaling. Integrins function
as a heterodimer, consisting of one α subunit and one
β subunit that associate noncovalently. Mammals have 24
distinct integrin receptors, formed from a total of 18 α sub-
units and 8 β subunits [3]. Integrins couple recognition of
ECM ligands to the assembly of the actin cytoskeleton and
the activation of various intracellular kinases [4]. Here, we
review recent studies that have deepened our understanding
of the dynamics and coordination of integrin signaling and
of the role that these signals play in mammary epithelial cells
and their malignant counterparts.
2. Integrins inNormal Mammary
Epithelial Cells
With a disease as diverse as breast cancer—in its histology,
genetic lesions, proliferation, response to treatment, and
propensity to metastasize—it is crucial to examine how the
cell type that is initially transformed impacts the tumor
that is subsequently formed, a concept which emphasizes
the cell of origin for a particular cancer [5]. In this regard,
new developments in the ﬁeld of mammary stem cells and
advances in understanding the mammary epithelial cell hier-
archy have paved inroads for those examining this concept in
breast cancer. And, perhaps not surprisingly, integrins have
already played a prominent role.
The epithelium of the mammary gland is composed of
luminal cells, which line the ducts and alveoli, and myoep-
ithelial cells which form the basal cell layer that sur-
rounds luminal cells and contacts the basement membrane,2 ISRN Oncology
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Figure 1: Integrin expression in the normal mammary gland. The α and β integrin subunits expressed in the mammary gland are listed
with the CD alias in parentheses. Their lineage expression pattern is indicated as L (luminal), M (myoepithelial), and L/M (luminal and
myoepithelial). ∗indicates a relatively low-level or restricted expression pattern. The lineage expression of the β3 integrin is not clear. The
functional integrin receptors and their ligand class are shown below. See [7, 10–12] for more information.
a specialized form of ECM rich in collagen IV and laminins
[6]. Integrin expression in the mammary epithelial cells is
complicated as it is regulated spatially and temporally as
the gland develops and through pregnancy, lactation, and
involution [7]. However, a few points regarding integrin ex-
pression in the mammary gland are useful here. First, mam-
mary epithelial cells are anchorage dependent and require
cell-cell interactions or integrin-mediated attachment to the
ECM; in the absence of such adhesion, a cell will not pro-
liferate in response to growth factors [8]a n dw i l ls u c c u m b
to a specialized form of apoptosis—anoikis—that occurs as a
result of detachment from the ECM [9].
Second, although integrin expression and activation can
vary within the gland, a somewhat limited set of integrins
are expressed—as assessed by immunohistochemistry—with
certain integrins restricted to either the luminal or myoep-
ithelial cells (Figure 1). In general though, as myoepithelial
cells make more extensive contact with the ECM, integrin
levels tend to be higher in this lineage [7]. The major α
subunits expressed include α1, α2, α3, α5, αva n dα6; the
expression of α1, α5, and αv appears to be restricted to
myoepithelial cells [7, 10]. The β1a n dβ4 integrin subunits
are expressed in both epithelial lineages of the gland, while
the β3 subunit exhibits a more restricted expression pattern
[7, 10, 11]. Thus, epithelial cells of the mammary gland are
capableofassemblingatleasteightfunctionalintegrinrecep-
torsincludingtwocollagenreceptors(α1β1,andα2β1),three
lamininreceptors(α3β1,α6β1,andα6β4)andthreeintegrins
(α5β1, αvβ1, and αvβ3) which recognize RGD sequences
present in certain ECM molecules such as ﬁbronectin and
vitronectin [3]. However, the relative expression level of
each complex, their potential interactions with the ECM,
and their ability to activate intracellular signaling—in short,
their functional status—are not reﬂected in the basic survey
of integrin expression presented above. This information
must be derived empirically, as some studies discussed below
demonstrate.
Finally, integrin expression is often polarized, with com-
plexes being localized to distinct membrane surfaces. The
best example here is the α6β4 integrin, which is found pre-
dominantly on the basal surface of myoepithelial cells [10].
The β4 integrin is unique in that it has a much longer cyto-
plasmic tail and connects with intermediate ﬁlaments in
place of the actin cytoskeleton [3]. The localization of the
α6β4 complex—a laminin receptor—to the basal surface
allows myoepithelial cells to adhere to the laminin rich base-
ment membrane through specialized adhesive complexes
referred to as hemidesmosomes [10]. Nevertheless, simple
examination of integrin expression patterns has been of only
limited use in understanding their function in the epithelial
cells of the mammary gland. And, as our knowledge of the
epithelial hierarchy has progressed, a more detailed view of
integrin signaling in the mammary gland has come into
focus.
Early experiments involving serial transplantation of
mammary epithelial fragments strongly supported the idea
that self-renewing stem cells existed in the mammary gland
[13]. A signiﬁcant milestone was reached in 2006 when
two reports used cell surface markers to isolate populations
enriched for mouse mammary stem cells, in which a single
stem cell could reconstitute a functional gland [14, 15]. Two
integrins, β1 (CD29) and α6 (CD49f), were used to purify
mammary stem cell populations with a cell surface pheno-
typeofCD29highCD24+ andCD49f
highCD24med,respectively .
Analogous studies have since been performed using human
cells and a humanized mammary fat pad transplantation
assay and, here too, high expression of α6 integrin (along
with the absence of EpCAM expression) was used to purify
a mammary stem cell enriched population [16]. The scope
of these studies was not to address the role of integrinsISRN Oncology 3
in mammary stem cells, but the results almost certainly
indicate that mammary stem cells possess a characteristic set
of integrins and suggest that these integrins, and therefore
distinct cell-ECM interactions, might have a functional role
in regulating the mammary epithelial cell hierarchy.
This notion has received some support in recent years,
mainly through the use of mammary-speciﬁc deletion of
integrins. Butprior to the development ofthese morereﬁned
models, knockout mice had been generated for all of the
α and β subunits present in the mammary gland [3]. Of
these mice, the α5[ 17] and the αv[ 18] are embryonic
lethal, restricting their applicability to mammary gland
development. Mice with deletion of the α1[ 19], α3[ 20], and
α6[ 21] subunits display no apparent mammary phenotype
[3, 7], but animals deﬁcient in the α2 subunit have impaired
mammary gland branching morphogenesis [22]. Knockout
of the β subunits present in the mammary gland give rise
to variable phenotypes ranging from embryonic lethality
for β1 integrin [23], hemorrhaging and defects in platelet
aggregation for β3 integrin [24], and severe skin blistering
and early death for β4 integrin [25] but no overt mammary
gland defects. It is likely, though, that the lack of any
mammary-speciﬁc ﬁndings in most of the models described
above is masked by the dramatic phenotypes observed dur-
ing development or in other organ systems, and thus does
not discount the relevance of these receptors to the epithelial
cells of the mammary gland.
Early eﬀorts to uncover the function of integrins in the
mammary gland utilized function-blocking antibodies di-
rected at β1a n dα6 integrins as well as an antilaminin anti-
body [26]. These studies found that blocking both laminin
and the β1 subunit, but not α6, impaired ductal morpho-
genesis, which was in line with a previous study that used
a dominant negative β1 integrin to demonstrate a role for
this subunit in alveolar diﬀerentiation [27]. It was surprising
then, when rudimentary glands isolated from α3, α6, or β4
knockout mice were able to undergo normal ductal morpho-
genesis when transplanted into syngeneic recipients [28].
But with the advent of techniques that allow genetic dis-
ruptions to be targeted to speciﬁc tissues at deﬁned times
during development, it has been possible to more closely
examine integrin function in the mammary gland. This is
especially true for β1 integrin (Table 1) ,w h i c hs e r v e sa sa
subunit for numerous integrin receptors found in the mam-
mary gland. Although conditional mammary deletion of β1
integrin—created by crossing mice ﬂoxed for β1 with trans-
genic mice that express Cre recombinase from the MMTV
promoter—develops normal mammary glands [29], two
reports published in 2005 were able to disrupt the β1 subunit
in a similar fashion, but instead crossed the ﬂoxed mice with
transgenicmicethatexpressCrerecombinasefromeitherthe
βlactoglobulin(Blg)orwheyacidicprotein(WAP)promoter
[30, 31]. This strategy allowed for conditional deletion of β1
integrin in deﬁned epithelial compartments and at certain
stagesofdevelopment;Blg-Cregivesrisetoβ1deletioninthe
ductal epithelium in nulliparous mice after puberty, while
WAP-Cre generates deletions in luminal alveolar cells during
mid-pregnancy. In both cases, deletion of the β1 subunit
impaired lobuloalveolar development and lactation, which
Table 1: Targeted deletions of β1 integrin in the mammary gland.
Cre promoter Phenotype Reference
MMTV No eﬀect on early gland
development [29]
whey acidic protein
(WAP)
Disorganized alevoli; inhibited
luminal cell proliferation [30]
β lactoglobulin (Blg) Impaired alveolar morphogenesis
and diﬀerentiation [31]
keratin 5
Depletion of mammary stem
cells; impaired regenerative
potential
[32]
was attributed to inhibition of luminal cell proliferation as
a result of increased p21Cip1 [30] and failure to diﬀerentiate
in response to prolactin [31].
β1 integrin has also been deleted from the basal cell pop-
ulationofthemammaryepitheliabyexpressingCrefromthe
keratin 5 (K5) promoter [32]. Interestingly, this resulted in a
depletion of mammary stem cells and produced glands that
lacked regenerative potential. Furthermore, dividing basal
cells lacking β1 integrin aberrantly gave rise to luminal cells.
These results expand upon the functions of this integrin
subunit in the mammary gland and strongly support the
idea that β1 integrin expression, and more generally distinct
cell-ECM interactions, play a crucial role in regulating the
epithelial cell hierarchy of the mammary gland.
While no conditional β4 knockout has been reported,
mice with targeted deletion of the C-terminal domain, which
allows for prolonged survival and reproduction, appear to
develop normally with no mammary gland defects reported
[33]. As β4 dimerizes with α6 integrin, this is in line with
studies, discussed above, that found no requirement for
α6 using function-blocking antibodies or mammary gland
transplants from α6 knockout mice [26, 28].
No conditional knockout in the mammary epithelium
exists for β3 integrin either, although this is likely because
the role of this subunit in the gland has only recently been
appreciated. A subpopulation of luminal progenitors—with
the capacity to diﬀerentiate into either ductal or alveolar
luminal epithelial cells—has been identiﬁed on the basis of
β3 integrin expression [11]. In this study, the authors found
that a subset of luminal cells, which are enriched in the
CD29lowCD24+ population [14],expresshighlevelsoftheβ3
integrin, form exclusively luminal colonies, and proliferate
extensively when grown in Matrigel. The percentage of β3
expressing cells decreases with pregnancy, ostensibly as a
result of luminal diﬀerentiation [11]. This integrin appears
to be a reliable and useful marker of luminal progenitors,
but similar to the integrins used to purify mammary stem
cells,whetherthesereceptorsandtheirdownstreamsignaling
pathways confer any distinct functions upon these subpopu-
lations is still an open question.
3. IntegrinSignalingin Breast Tumorigenesis
3.1. Basic Integrin Signaling Mechanisms. Integrin recogni-
tion of ECM proteins induces allosteric changes that allow4 ISRN Oncology
the receptor to transduce this signal across the membrane,
a process referred to as outside-in signaling [3]. As inte-
grins possess no enzymatic function, activation of integrin
receptors results in the association of multiple protein
complexes with the short cytoplasmic tails of the integrins.
This allows integrins to transmit mechanical signals to
the actin cytoskeleton (and in the case of β4 integrin, to
intermediate ﬁlaments) through proteins such as α-actinin,
tensin,paxillin,andvinculinaswellasbiochemicalsignalsby
way of tyrosine kinases such as focal adhesion kinase (FAK)
orSrc[34].Tyrosinekinasesignalingleadstotherecruitment
of numerous adaptor proteins including p130Cas, Crk, and
the IPP complex, which further propagate the signal within
the cell [35]. While the eﬀects of integrin signaling are varied
and dependent on both the ECM ligand and speciﬁc integrin
receptor engaged, these receptors function essentially to
control cell migration, proliferation, and survival.
Integrin signaling occurs in cooperation and coordi-
nation with growth factor signaling that is initiated from
soluble factors in the extracellular environment. This makes
sense as epithelial cells are anchorage dependent and require
adhesion, mediated by integrins, in order to proliferate in
response to growth factors [8]. Crosstalk between integrin
and growth factor signaling occurs at many diﬀerent levels.
For one, integrins and growth factor receptors can activate
similar downstream signaling pathways such as tyrosine
kinases and the MAP kinase pathway, and this combined
activation can further amplify the signal [36]. Upon activa-
tion, integrins and growth factors receptors cluster together
in the membrane and appear to physically interact with each
other, which may also help to coordinate signaling [37].
For example, α6β4a n dα6β1 integrins have been found in
association with ErbB2 (HER2), and this interaction may
help to potentiate signaling [38]. There is also evidence that
integrins can activate growth factor receptors by promoting
phosphorylation of the receptor [39] or by stimulating the
production and secretion of the growth factor itself [40].
Finally, expression of integrins and growth factor receptors
can be coordinated; as an example, α6β4 can enhance
ErbB2 translation [41]. Although many of the mechanisms
described here have been elucidated in tumor cells, or
cells overexpressing the integrin or growth factor receptor,
the coordination of integrin and growth factor signaling is
well established. And while the dynamics of these signaling
networks that operate in normal mammary epithelial cells
are less clear, the integrin and growth factor pathways are
inextricably linked as is evident from morphological and
functional studies of the mammary gland [10, 42].
Integrin receptors are unique in that they can also trans-
mit signals emanating within the cell to the extracellular
environment in what is known as inside-out signaling [3].
In this mode of signal transduction, interactions from the
cytoplasmic tail are conveyed to the extracellular domain
through conformational changes. This type of signaling
is especially important when integrin activation must be
strictly regulated, as in the case of platelets [3]. In epithelial
cells, however, this bidirectional communication allows inte-
grins to control remodeling of the ECM [43]. Furthermore,
since the matrix proteins bind numerous growth factors
and regulate their availability, reorganization of the ECM by
integrins can liberate occult soluble signals [44].
3.2. Deregulation of Integrins in Breast Cancer. Integrins are
not considered to be bona ﬁde oncogenes or tumor suppres-
sorsbuttheirexpressionlevelsareaﬀectedbytransformation
[45] and breast cancer cells exhibit altered levels of integrin
expression[46].Nocharacteristicintegrinexpressionpattern
can be ascribed to all breast tumors, and it is likely that
diﬀerent subtypes of breast cancer [47]m a yg e n e r a t et u m o r s
with distinct integrins. Some support for this idea comes
from recent studies [16, 48, 49] that have identiﬁed luminal
progenitors—deﬁned in part by their expression level of
α6 integrin [16]—as the transformed cell of origin which
gives rise to basal-like tumors. Nevertheless, certain integrins
are commonly deregulated in breast cancer. On one hand,
the α6[ 50], β4[ 51], and αv[ 52] integrins are generally
overexpressed in aggressive breast cancer cells. On the other
hand, expression of α2β1 can be suppressed during the
process of transformation [53]. Ultimately though, it is the
function of integrins in tumors cells that is most relevant.
Below, we highlight some recent advances pertaining to
integrin function in breast cancer cells.
3.3. Integrin Signaling in Tumor Initiation. Integrins have
begun to emerge as key players in breast tumor initiation.
Based in part on the cooperatively of integrin and growth
factor signaling described above, a mammary speciﬁc dele-
tion of β1 integrin was generated in a transgenic mouse
model of breast cancer in which the polyomavirus middle T
antigen(PyVmT)oncogene,anactivatorofmanyofthesame
signaling pathways downstream of growth factor receptors
[54], is expressed from the MMTV promoter [29]. Here, loss
of β1 integrin severely impaired tumorigenesis indicating
a crucial role for this integrin in cell transformation and
the initiation of mammary tumors that arise in this model.
In line with this, deletion of β1i m p a i r e dc e l lp r o l i f e r a t i o n
and FAK phosphorylation, which was shown to mark
hyperplastic regions of the gland [29] and is known to
regulate entry into the cell cycle [55].
Similar ﬁndings have been described for β4 integrin
in an ErbB2 overexpressing mouse model of breast cancer
[56]. In this case, deletion of the β4 cytoplasmic domain,
which suppresses intracellular signaling, resulted in an
increased latency and reduced aggressiveness of ErbB2-
induced tumors. A protein complex containing both ErbB2
and α6β4 integrin could be detected, and this ampliﬁed
downstream activation of the transcription factors c-Jun
and STAT3 to facilitate cell proliferation and suppression of
apoptosis. Further, β4 integrin signaling enhanced resistance
to the ErbB2 inhibitor Iressa, presumably as a consequence
of enhanced oncogenic signaling [56].
The results of these studies support two key points:
(1) integrin and growth factor signaling collaborate in vivo
during tumorigenesis and (2) integrins actively participate
in the process of tumor initiation. It is worth noting, that
several factors downstream of integrins have also beenISRN Oncology 5
deleted in the context of the MMTV-PyVmT model of mam-
mary tumorigenesis. Although ablation of FAK decreased
proliferation of tumor cells, it only moderately increased the
latency of tumor development, and FAK was not required
for the generation of mammary tumors [57]. However, it
does seem to have a role in tumor progression as cancer cells
lacking FAK were not able to metastasize [57]. Deletion of
Src in the same tumor model has similar eﬀects including
delayed tumor onset, proliferation and cell cycle defects, and
impaired tumor progression [58]. The discrepancy between
these studies and the β1a n dβ4 deletions suggests that
integrins may use distinct signaling pathways at diﬀerent
times during tumorigenesis to regulate both tumor initiation
and tumor progression.
3.4. Integrin Signaling in Cancer Stem Cells. An exciting area
of breast cancer research is the study of cancer stem cells.
The cancer stem cell hypothesis predicts that a certain sub-
population of tumor cells—ﬁrst identiﬁed for breast cancer
in 2003 [59]—drives tumor growth, progression and recur-
rence [60]. This theory has strong implications for the treat-
ment of cancer, and so there has been a concerted eﬀort to
understand the signals which maintain this population in
hopes of developing strategies to therapeutically target this
tumorigenicpopulation[61].Recentworkhassuggestedthat
integrin signaling may have a functional role in the cancer
stem cells [12].
In2008,astudyofvariousmousemammarytumormod-
els found that MMTV-Wnt1 mice exhibited aberrant regu-
lationofmammaryepithelialcellpopulations—asdeﬁnedby
CD29 (β1 integrin) and CD24 [14]—prior to tumorigenesis
with expansion of the CD29highCD24+ population of mam-
mary stem cells [62]. Importantly, β3 integrin expression
marked a population of cancer stem cells that was highly tu-
morigenic. These results imply that Wnt1-induced tumor-
igenesis arises from an altered pool of luminal progenitors
[62], but similar to normal luminal progenitors [11], it re-
mains to be seen whether signaling from β3 integrin is re-
levant in this context.
Interestingly, FAK has also been implicated in the control
of mammary and cancer stem cells. In a separate study
where FAK was deleted in MMTV-PyVmT mice, the authors
found a reduced pool of mammary stem cells that exhibited
defects in self-renewal that were associated with impaired
tumorigenesis [63]. This ﬁnding is especially interesting in
the light of the fact that β1 integrin is also involved in
mammary stem cell regulation [32] and seems to indicate a
key role for integrin signaling in stem cells, which may be
coopted during tumorigenesis [64]. It would be interesting
then to test the role of β1 integrin and FAK in the MMTV-
Wnt1model,whereadeﬁnedcancerstemcellpopulationhas
been identiﬁed [62].
4. Integrinsand BreastCancer Progression
4.1. Integrins Signaling in Migration and Invasion. In cancer,
integrins are perhaps best known for their role in cell mi-
gration and tissue invasion [65]. Migration and invasion are
a prerequisite for the complex process of metastasis which
is thought to occur through a series of steps involving local
tissue invasion, intravasation, survival in the circulation,
extravasation, and colonization [66]. The ECM of the mam-
mary gland serves as an inherent barrier to tumorigenesis
and metastasis, so tumor cells must ﬁnd ways to circumvent
this suppressive force [67]. As integrins interact directly
with the ECM and can control remodeling of the matrix,
tumor cells can beneﬁt from altered integrin expression and
signaling in the context of metastasis. To metastasize, tumor
cells must ﬁrst be able to migrate. Integrins surely play a role
in the process of cell migration and likely function at two
diﬀerent levels. First, integrins must coordinate and stabilize
adhesion to the ECM in such a way that allows for cell
movement,formingstrongadhesivecomplexesattheleading
edge of the cell while releasing previous points of contact
at the trailing end [68]. At another level, integrins couple
actin reorganization to cellular signals that regulate motility
through activation of PI3-kinase and small GTPases such as
Cdc42 and Rac [69]. Other integrin signaling pathways are
importantaswell;forinstance,FAKisrequiredforepidermal
growth factor-induced cell motility [70].
In addition to their central role in cell motility, integrins
have recently been shown to actively participate in the tran-
sition of a nonmotile tumor cell to an invasive, malignant
cell.Throughaprocessreferredtoasepithelial-mesenchymal
transition (EMT), tumor cells can gain access to signaling
programs, normally reserved for development, that allow
epithelial cells to migrate and invade the surrounding tissue
[71]. EMT can be induced in susceptible breast cancer by the
cytokineTGF-β [72],butstudieshaveshownthatβ3integrin
signaling and Src activation are required for this occurrence
in mammary epithelial cells [73]. Other integrins, with a less
established role in breast cancer, such as αvβ6 integrin, have
been shown to regulate the release of active TGF-β from the
ECM [44], but the relevance of this to breast cancer might be
limited.
The induction of EMT is associated with the expression
of matrix metalloproteinases (MMPs) that can degrade
a n dr e m o d e lt h eE C M[ 74]. The αvβ3 integrin, which is
overexpressedincertainbreastcancers[52],caninteractwith
and enhance the activation MMP-2 in melanoma cells to
promote invasion [75], and a similar mechanism could ben-
eﬁt breast cancer cells which express the same combination
of proteins. Alternatively, αvβ3 may enhance the expression
of MMP-2 [76]. The association of αvβ3 with the urokinase
plasminogen activator receptor (uPAR) provides yet another
example of how integrins can modulate degradation of the
ECM to facilitate breast cancer invasion [77].
4.2. Integrins and Metastasis. An association between the
expression of certain integrins and the metastatic spread
of breast cancer has been suspected for some time. Of
note here is the association between high αvβ3 expression
and bone metastasis [78], the reduced expression of α2β1
observed in poorly diﬀerentiated adenocarcinomas [79]a n d
the correlation of high α6 expression with reduced survival
[50]. However, recently, new mechanisms by which integrins
regulate metastasis have been elucidated.6 ISRN Oncology
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Figure 2: Roles of integrin signaling in mammary epithelial cells and breast cancer progression.
Early eﬀorts to explain the connection between αvβ3
expression and metastasis found that activation of this inte-
grin could help breast cancer cells adhere to platelets, an in-
teraction which may help disseminated cancer cells arrest
in the circulation prior to extravasation [80]. However, this
integrin receptor may exert a more direct eﬀect on tumor
cells by activating intracellular signals, in the absence of cell
adhesion, that promote tumor progression [81]. In line with
previous studies, the authors observed that expression of this
integrinwashigherinlymphnodemetastasesandfoundevi-
dence to suggest that this was a result of enhanced tumor cell
survival [81]. Most surprising though, they found that un-
ligated αvβ3 promoted anchorage-independent growth, and
presumably tumor progression, through a mechanism that
involves recruitment of Src and phosphorylation of CAS.
This ﬁnding is especially interesting as it suggests that tumor
cells utilize integrin signaling independent of cell adhesion
and it has clinical relevance as many αvβ3 inhibitors target
the ligand binding, which is apparently dispensable here
[81]. However, neither of these studies explain why αvβ3
expression is preferentially retained in breast cancer cells that
metastasize to the bone.
New information also highlights the extensive crosstalk
between integrins and other oncogenic proteins that are
active in tumor cells. A recent report described a new mech-
anism by which mutant p53 can contribute to cancer cell
invasion and metastasis [82]. This study found that mutant
p53 promotes increased endocytic traﬃcking of EGFR and
α5β1 integrin to the plasma membrane through Rab-coup-
ling protein (RCP), which leads to enhanced integrin and
growthfactorsignalingthatisrequiredforcellmigrationand
invasion. These results support the recent ﬁnding that RCP is
oncogenic in mammary epithelial cells [83] and suggest that
integrin signaling might be required for RCP to function in
this manner.
Integrins can also collaborate with inhibitor of apoptosis
(IAP) proteins to promote breast cancer metastasis [84].
While IAPs are typically thought of as antiapoptotic proteins
itappearsthattheirfunctionsaremorevariedthanoriginally
thought[85].Buildinguponthis,istherecentﬁndingthatan
XIAP-survivin complex can also regulate tumor cell invasion
and metastasis, independent of its antiapoptotic eﬀects [84].
I A P sa r ea b l et od ot h i sb ya c t i v a t i n gN F - κB, which induces
the production of ﬁbronectin. Secreted ﬁbronectin can then
act in an autocrine or paracrine to stimulate β1 integrin
signaling through FAK and Src [84].
It is important to note that not all integrins promote tu-
mor progression and metastasis. For instance, a recent report
has clearly established that the α2β1 integrin is a metas-
tasis suppressor in breast cancer [86]. Deletion of α2β1 in-
tegrin in the MMTV-ErbB2 mouse signiﬁcantly increased
the incidence of metastasis without aﬀecting growth of the
primary tumor. This seems to occur at the level of cancer cell
intravasation as tumors devoid of α2β1 produced increased
numbersof circulatingtumorcellswhiletailvein injection—
a test of tumor cell extravasation and colonization—of the
same cells did not aﬀect metastasis [86]. Using clinical data-
bases of gene expression, reduced α2β1 expression was
strongly correlated to metastasis and decreased survival [86],
but the molecular basis underlying this eﬀect remains to be
established.
5. Concluding Remarks
Integrins have a long and storied history in the breast
cancer literature and clearly their central role as sensors and
transducers of ECM signals is without question. But it has
taken some time—with the diverse array of integrins and
ECM ligands—to fully appreciate their function. This paper
has touched only upon the cell-autonomous functions of
integrinsinepithelialcellsofthemammaryglandandduring
breast cancer progression (Figure 2), but their expression
in other cell types such as endothelial cells, ﬁbroblasts and
lymphocytes also contributes to tumorigenesis [87]. Given
their role in breast cancer and the availability of integrin
antagonists, preclinical studies and clinical trials are cur-
rently underway to test the eﬃcacy and tolerability ofISRN Oncology 7
these agents [88]. However, important questions regarding
integrin signaling still remain. How the ECM changes that
occur with cancer development and disease progression
aﬀect integrin signaling in tumor cells is an important area
of focus. This would seem to be especially true in the con-
text of metastatic colonization [89], where tumor cells en-
counter an entirely new ECM and are still able to thrive;
surely integrins must have a crucial function here. The
relevance of integrin signaling in normal mammary stem
cells, luminal progenitors, and other mammary epithelial
cell populations is still largely unknown, but it is likely that
integrins are involved in regulation of this hierarchy and
therefore, perturbed integrin signaling may have distinct
eﬀects in diﬀerent subtypes of breast cancer. For it is only by
deﬁning the precise role of integrin signaling in the normal
mammary gland that we will be able to appreciate the true
extent of its contribution to breast cancer.
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